Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 23:2021:8030297.
doi: 10.1155/2021/8030297. eCollection 2021.

Bifidobacterium Longum: Protection against Inflammatory Bowel Disease

Shunyu Yao  1 , Zixi Zhao  1 , Weijun Wang  1 , Xiaolu Liu  1
Affiliations
Review

Bifidobacterium Longum: Protection against Inflammatory Bowel Disease

Shunyu Yao et al. J Immunol Res. .

Abstract

The prevalence of inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), increases gradually worldwide in the past decades. IBD is generally associated with the change of the immune system and gut microbiota, and the conventional treatments usually result in some side effects. Bifidobacterium longum, as colonizing bacteria in the intestine, has been demonstrated to be capable of relieving colitis in mice and can be employed as an alternative or auxiliary way for treating IBD. Here, the mechanisms of the Bifidobacterium longum in the treatment of IBD were summarized based on previous cell and animal studies and clinical trials testing bacterial therapies. This review will be served as a basis for future research on IBD treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest to report.

Figures

Figure 1
Figure 1
Protective mechanism of Bifidobacterium longum against intestinal inflammation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ananthakrishnan A. N. Epidemiology and risk factors for IBD. Nature Reviews. Gastroenterology & Hepatology. 2015;12(4):205–217. doi: 10.1038/nrgastro.2015.34. - DOI - PubMed
    1. Ng S. C., Shi H. Y., Hamidi N., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390(10114):2769–2778. doi: 10.1016/S0140-6736(17)32448-0. - DOI - PubMed
    1. Kaplan G. G. The global burden of IBD: from 2015 to 2025. Nature Reviews Gastroenterology & Hepatology. 2015;12(12):720–727. doi: 10.1038/nrgastro.2015.150. - DOI - PubMed
    1. Parada Venegas D., de la Fuente M. K., Landskron G., et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Frontiers in Immunology. 2019;10 doi: 10.3389/fimmu.2019.00277. - DOI - PMC - PubMed
    1. Fourie S., Jackson D., Aveyard H. Living with Inflammatory Bowel Disease: A review of qualitative research studies. International Journal of Nursing Studies. 2018;87:149–156. doi: 10.1016/j.ijnurstu.2018.07.017. - DOI - PubMed

MeSH terms

LinkOut - more resources